As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Amgen shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and rocatinlimab, ...

Shares of Amgen AMGN fell by more than 5% on Wednesday after it reported top-line data on two different drugs in the ...

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Amgen (AMGN – Research Report) yesterday and set a price target of $335.00.

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...

In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...

Jefferies analyst Michael Yee in a note to investors called rocatinlimab’s atopic dermatitis data “modest,” noting that the ...

Bank of America Securities analyst Charlie CY Yang has maintained their neutral stance on AMGN stock, giving a Hold rating today. Charlie CY ...

Changing the game with evidence and efficacy Speaking with Kristina Patterson of Horizon Therapeutics, pharmaphorum discussed the recent data presented on UPLIZNA as a treatment for NMOSD at the ...

The company is testing its drug, inebilizumab or Uplizna, in patients suffering from myasthenia gravis, which is caused by an ...

Amgen (AMGN) shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and ...